September 25, 2015
Recall of Murfy Farm’s alfalfa hay
Murphy Farm Hay and Feed Company of Louisburg North Carolina have initiated a voluntary limited recall of alfalfa hay due to…
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
September 25, 2015
Tresiba and Ryzodeg get FDA’s approval
The U.S. Food and Drug Administration has approved Tresiba (insulin degludec injection) and Ryzodeg 70/30 (insulin degludec/insulin aspart injection) to…
September 25, 2015
Johnson & Johnson completes divestiture of Splenda Brand to Heartland Food Products Group.
Johnson & Johnson Consumer Inc. has completed the divestiture of Splenda Brand to Heartland Food Products Group. Johnson & Johnson announced…
September 25, 2015
CHMP reccomends Bayer’s Eye medicine for approval in EU
The European Committee for Medicinal Products for Human Use (CHMP) has recommended Bayer’s aflibercept solution for injection into the eye…
September 25, 2015
Bayer: Factor Xa inhibitor Xarelto approved in Japan
The Japanese Ministry of Health, Labor and Welfare (MHLW) has approved in Japan Bayer’s oral Factor Xa inhibitor Xarelto (rivaroxaban) for the treatment…
September 25, 2015
Novartis: New NIBR director named. Entresto closer to be available EU
Switzerland-based Novartis has today appointed Dr. James E. Bradner, physician-scientist from Dana-Farber Cancer Institute and Harvard Medical School, as President of the…
September 25, 2015
‘Novartis Access’, a portfolio of affordable medicines to treat chronic diseases in lower-income countries
Novartis has announced the launch of Novartis Access, a portfolio of 15 medicines to treat chronic diseases in low- and…
September 23, 2015
NIh: Clomiphene shows better results than letrozole for unexplained infertility
Treatment with clomiphene, a standard therapy for couples with unexplained infertility, results in more live births than treatment with a…
September 23, 2015
Phase 3 study of ABP 215 meets its endpoints
Amgen and Allergan plc. announced on Wednesday that a Phase 3 study of biosimilar candidate ABP 215 met its primary…
September 23, 2015
ViiV Healthcare announces results from STRIIVING HIV-1 study
ViiV Healthcare announced on Wednesday 24-week data from the Phase IIIb/IV Striiving study, an open-label study evaluating the efficacy, safety…